ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1334

Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies

Jiram Torres-Ruíz1, Araceli Leal-Alanis2, Ricardo Vazquez-Rodriguez3, Mario René Alvarado-Lara3, Edgar Rafael Carazo-Vargas3, José Luis Maravillas-Montero4, Jorge Alcocer-Varela5 and Diana Gómez-Martín5, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico, 2Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 4Red de Apoyo a la Investigación, UNAM, Mexico, Mexico, 5Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Myositis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Low density granulocytes (LDGs) are a subset of neutrophils that spontaneously produce neutrophil extracellular traps (NETs) and type I IFN. The latter correlates with disease activity and IFN regulated genes had been found in atrophic muscle fibers of patients with idiopathic inflammatory myopathies (IIM). However, the role of this subset of neutrophils has not been fully addressed in IIM. The aim of this study was to assess the relationship between LDGs, disease activity and damage in patients with IIM.

Methods: We recruited 65 adult patients with dermatomyositis, polimyositis, and anti-synthetase syndrome according to the respective classification criteria. The percentage and absolute number of LDGs were assessed by flow cytometry as those CD10+, CD15+and CD14–cells in the mononuclear fraction. Disease activity and damage were evaluated by two Rheumatologists. Complete clinical response was defined as the absence of muscular and extra muscular disease activity with immunossupressive therapy.

Results: The most frequent diagnosis was adult onset dermatomyositis (67.6%). Patients with calcinosis and dysphagia had higher amount of LDGs (Table 1). There was a trend towards higher amount of LDGs in patients with anti MDA5 antibodies. LDGs correlated with disease activity scales (MMT8, muscle enzymes, the patient’s and physician’s visual analogue scale (VAS) of disease activity) as well as with the extension and severity of damage (Table 2). Only 23.9% of patients had clinical complete response and those subjects had significantly lower levels of LDGs (0.17 (0.08-0.49) vs 0.46 (0.23-1.35), P=0.030).

Conclusion: LDGs are expanded in subjects with active IIM, especially in those with signs of vasculopathy (calcinosis) and dysphagia. LDGs correlate with disease activity and damage scales. Also, patients with anti MDA5 antibodies whom are characterized by an intense IFN signature have higher amount of LDGs. Our findings support the role of LDGs in the induction of disease activity and damage in patients with IIM and suggest that they may serve as a biomarker to identify patients with active disease in contrast with those with complete clinical response.

Table 1.

Feature

Present

Absent

P

Calcinosis

1.17 (0.35-2.52)

0.32 (0.15-0.91)

0.035

Dysphagia

1.66 (0.28-2.7)

0.32 (0.15-0.83)

0.028

Anti-MDA5

2.37 (2.17-)

0.27 (0.1-0.84)

0.076

Table 2.

Feature

Rho

P

Feature

Rho

P

MMT8

-0.4

0.001

Neutrophil/ lymphocyte ratio

0.31

0.013

Physician VAS

0.310

0.012

Patient VAS

0.308

0.013

ALT

0.319

0.011

AST

0.298

0.018

Muscle damage VAS

0.339

0.001

Cutaneous damage VAS

0.31

0.011

Damage extension

0.324

0.009

Damage severity

0.297

0.017


Disclosure: J. Torres-Ruíz, None; A. Leal-Alanis, None; R. Vazquez-Rodriguez, None; M. R. Alvarado-Lara, None; E. R. Carazo-Vargas, None; J. L. Maravillas-Montero, None; J. Alcocer-Varela, None; D. Gómez-Martín, None.

To cite this abstract in AMA style:

Torres-Ruíz J, Leal-Alanis A, Vazquez-Rodriguez R, Alvarado-Lara MR, Carazo-Vargas ER, Maravillas-Montero JL, Alcocer-Varela J, Gómez-Martín D. Low Density Granulocytes As Biomarkers of Disease Activity and Damage in Patients with Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/low-density-granulocytes-as-biomarkers-of-disease-activity-and-damage-in-patients-with-idiopathic-inflammatory-myopathies/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-density-granulocytes-as-biomarkers-of-disease-activity-and-damage-in-patients-with-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.